Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 69 citing articles:

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Matteo Megna, Nello Tommasino, Luca Potestio, et al.
Journal of Dermatological Treatment (2022) Vol. 33, Iss. 6, pp. 2813-2820
Closed Access | Times Cited: 69
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 17
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
Marco Galluzzo, Mark S. Talamonti, Arnaldo Cioni, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2631-2631
Open Access | Times Cited: 49
Staphylococcus aureus skin colonization promotes SLE-like autoimmune inflammation via neutrophil activation and the IL-23/IL-17 axis
H. Terui, Kenshi Yamasaki, Moyuka Wada‐Irimada, et al.
Science Immunology (2022) Vol. 7, Iss. 76
Closed Access | Times Cited: 39
Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
Andrew Blauvelt, Andrea Chiricozzi, Benjamin D. Ehst, et al.
Advances in Therapy (2023) Vol. 40, Iss. 8, pp. 3410-3433
Open Access | Times Cited: 27
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 1, pp. 93-103
Open Access | Times Cited: 32
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2021) Vol. 113, Iss. 3, pp. 261-277
Open Access | Times Cited: 39
Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
Athanasios Tsianakas, Uwe Schwichtenberg, Peter Pierchalla, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 1, pp. 85-92
Open Access | Times Cited: 26
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge
Angelo Ruggiero, Elisa Camela, Luca Potestio, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 12, pp. 1445-1451
Closed Access | Times Cited: 26
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Hidehisa Saeki, Tomotaka Mabuchi, Akihiko Asahina, et al.
The Journal of Dermatology (2022) Vol. 50, Iss. 2
Open Access | Times Cited: 24
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2022) Vol. 113, Iss. 6, pp. 583-609
Open Access | Times Cited: 23
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim Papp, Andrew Blauvelt, L. Puig, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1149-1158
Open Access | Times Cited: 16
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
Elena Campione, Sara Lambiase, Ruslana Gaeta Shumak, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 526-526
Open Access | Times Cited: 12
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice
Antonio Costanzo, Mar Llamas‐Velasco, Gabriella Fabbrocini, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 10, pp. 2004-2015
Open Access | Times Cited: 11
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
S. Wu, Yuanyuan Xu, Lihua Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023
Jinger Lin, X.Y. Chen, Min Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Patient's Perspective on the Impact of Psoriasis on Their Quality of Life After 1 Year of Tildrakizumab Treatment: Despite Clinical Improvement, Persistence of a Potential Mental Cicatricial Memory of the Disease
Z. Reguiaï, Pierre André Becherel, Jean Perrot, et al.
JEADV Clinical Practice (2025)
Open Access
The optimal use of tildrakizumab in the elderly via improvement of Treg function and its preventive effect of psoriatic arthritis
Takemichi Fukasawa, Takashi Yamashita, Atsushi Enomoto, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden
Paolo Dapavo, Martina Burlando, Claudio Guarneri, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 133-138
Open Access | Times Cited: 3
Anti-IL 23 biologics for the treatment of plaque psoriasis
Alan Vu, Caden Ulschmid, Kenneth B. Gordon
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1489-1502
Closed Access | Times Cited: 15
Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest
Alexander Egeberg, D. Jullien, Kristian Gaarn du Jardin, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 8
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations
Marco Galluzzo, Andrea Chiricozzi, Élisa Cinotti, et al.
Expert Opinion on Biological Therapy (2021) Vol. 22, Iss. 3, pp. 367-376
Open Access | Times Cited: 20
Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis
Marta Krzysztofik, Paweł Brzewski, Przemysław J. Cuber, et al.
Pharmaceuticals (2023) Vol. 17, Iss. 1, pp. 14-14
Open Access | Times Cited: 7
Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)
Zaki Al‐Yafeai, Manush Sondhi, Kavya Vadlamudi, et al.
International Journal of Cardiology (2024) Vol. 402, pp. 131819-131819
Closed Access | Times Cited: 2
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3778-3791
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top